05/19/22 7:00 AMNasdaq : ALRN clinical trialAileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast CancerAileron is developing ALRN-6924 to protect patients with p53 mutated cancers against chemotherapy-induced bone marrow toxicities and other toxicities Trial is evaluating ALRN-6924 as a treatment to prevent chemotherapy-induced neutropenia, other bone marrow toxicities, and toxicities outside of theRHEA-AIneutral
05/17/22 7:00 AMNasdaq : ALRN conferencesAileron Therapeutics to Present at the H.C. Wainwright Global Investment ConferenceAileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer,RHEA-AIneutral
05/13/22 7:00 AMNasdaq : ALRN conferencesAileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that it will host a virtual KOL investor event on Thursday, May 19,RHEA-AIneutral
05/10/22 12:43 PMNasdaq : ALRN clinical trialAileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming Society for Investigative Dermatology 2022 Annual MeetingTaxanes, such as paclitaxel and docetaxel, cause severe and often permanent chemotherapy-induced hair loss (alopecia) New non-clinical data demonstrate proof of principle that ALRN-6924 can temporarily arrest the cell cycle in human scalp hair follicles and their stem cells ALRN-6924-induced cellRHEA-AIneutral
05/05/22 4:15 PMNasdaq : ALRN earningsAileron Therapeutics Reports First Quarter 2022 Financial Results and Business HighlightsOn track to report interim results from Phase 1b clinical trial of ALRN-6924 in patients with advanced p53-mutated non-small cell lung cancer (NSCLC) in June 2022; topline results anticipated in 4Q 2022 On track to initiate Phase 1b clinical trial of ALRN-6924 in patients with p53-mutated ER+/HER2-RHEA-AIneutral
04/21/22 8:00 AMNasdaq : ALRN managementAileron Expands Management Team with Appointment of Christopher Zergebel As Vice President, Program Management and Clinical OperationsMr. Zergebel brings over 20 years of industry experience, primarily focused in oncology, and broad expertise to help Aileron ensure operational excellence Aileron is advancing ALRN-6924 with the goal of delivering a chemoprotective agent for patients with p53-mutated cancer Clinical trial ofRHEA-AIneutral
03/28/22 4:20 PMNasdaq : ALRN earningsAileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business HighlightsSeveral anticipated catalysts in 2022 aim to advance Aileron’s vision to bring chemoprotection against multiple toxicities to all patients with p53-mutated cancer regardless of type of cancer or chemotherapy Expected readouts for Phase 1b trial in p53-mutated non-small cell lung cancer (NSCLC):RHEA-AIneutral
03/22/22 8:04 AMNasdaq : ALRN conferencesAileron Therapeutics to Participate in Maxim Group 2022 Virtual Growth ConferenceAileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to develop medicines to make chemotherapy safer and thereby more effective to save more patients’ lives, announced today that Manuel Aivado, M.D., Ph.D., President andRHEA-AIneutral
01/05/22 8:04 AMNasdaq : ALRN Aileron Therapeutics Provides Business Update and Outlines 2022 Strategic Priorities to Deliver Key MilestonesPlans to initiate Phase 1b clinical trial of ALRN-6924 in neoadjuvant breast cancer in 1H22; interim results expected in 4Q22 Planned readouts for ongoing randomized, double-blind, placebo-controlled non-small cell lung cancer (NSCLC) trial on track for interim results in 2Q22 and topline resultsRHEA-AIneutral
01/04/22 8:45 AMNasdaq : ALRN conferencesAileron Therapeutics to Present at Upcoming Investor ConferencesAileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, is pleased to announce that Manuel Aivado, M.D., Ph.D., President and Chief ExecutiveRHEA-AIneutral